PUBLISHER: The Business Research Company | PRODUCT CODE: 1666472
PUBLISHER: The Business Research Company | PRODUCT CODE: 1666472
Cardiac biomarkers represent substances released by the heart into the bloodstream during periods of injury or stress, aiding in the detection and measurement of various cardiac and vascular conditions.
The primary categories of cardiac biomarkers encompass creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), among others. Creatine kinase (CK) is an enzyme present in multiple body tissues, including muscles and the brain, commonly utilized in diagnosing myocardial infarction (MI), commonly known as a heart attack. These biomarkers find application across diverse testing settings such as point-of-care and laboratory-based assessments. They serve multiple diagnostic purposes, including testing for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), atherosclerosis, among other cardiac conditions. Hospitals and specialized clinics heavily rely on these biomarkers in their diagnostic protocols.
The cardiac biomarkers market research report is one of a series of new reports from The Business Research Company that provides cardiac biomarkers market statistics, including cardiac biomarkers industry global market size, regional shares, competitors with a cardiac biomarkers market share, detailed cardiac biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac biomarkers industry. This cardiac biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cardiac biomarkers market size has grown rapidly in recent years. It will grow from$18.99 billion in 2024 to $21.32 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increased healthcare expenditure, FDA approvals and regulatory support, aging population, awareness programs, high sensitivity troponin tests, increasing cardiovascular diseases
The cardiac biomarkers market size is expected to see rapid growth in the next few years. It will grow to $36.51 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising burden of chronic diseases, growing emphasis on early disease detection, expansion of geriatric population, emerging markets development, focus on biomarker panels. Major trends in the forecast period include patient-centric healthcare models, ai and machine learning applications, digital health integration, technological innovations in biomarker discovery, multi-marker panels, liquid biopsy in cardiovascular medicine.
The increasing prevalence of cardiovascular disorders is expected to drive the growth of the cardiac biomarker market. Cardiovascular disorders encompass diseases that affect the heart and blood vessels, including conditions like coronary artery disease, heart failure, and stroke. Cardiac biomarkers are substances released into the bloodstream in response to various cardiovascular issues, such as myocardial infarction (heart attack), heart failure, and arrhythmias. These biomarkers can be measured through laboratory tests, providing critical diagnostic and prognostic insights. For example, in September 2024, data from the British Heart Foundation, a UK-based cardiovascular research charity, revealed that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with around 4 million men and 3.6 million women living with these conditions. These diseases account for about 27% of all deaths in the UK, resulting in over 170,000 fatalities each year, or roughly 480 deaths per day, which equates to one death every three minutes. Therefore, the growing prevalence of cardiovascular disorders is fueling the expansion of the cardiac biomarker market.
The increase in healthcare expenditures is anticipated to drive the growth of the cardiac biomarker market. Healthcare expenditures encompass all costs related to health services, family planning, nutrition programs, and emergency health assistance, with a specific focus on improving health outcomes. Investment in cardiac biomarkers is aimed at enhancing early detection, enabling personalized treatment, and ensuring efficient resource allocation, which can potentially lower the overall costs associated with cardiovascular diseases. For example, a report from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a mere 0.9% growth in 2022. Consequently, the increase in healthcare expenditures is fueling the expansion of the cardiac biomarker market.
Technological advancements are becoming a prominent trend in the cardiac biomarker market. Companies in this sector are increasingly adopting new technologies to maintain their competitive edge. For example, in October 2023, Mindray, a China-based medical devices company, introduced new high-sensitivity cardiac biomarkers, troponin I (hs-cTnI) and NT-proBNP, aimed at improving the diagnosis and management of cardiovascular diseases (CVDs). The hs-cTnI biomarker is crucial for detecting myocardial injury, offering an impressive detection rate and low variability, making it essential for early screening and risk assessment in conditions such as Acute Coronary Syndrome (ACS). On the other hand, NT-proBNP is a well-recognized marker for heart failure, aiding in its detection and management while demonstrating high precision and minimal interference from commonly prescribed heart medications. Together, these biomarkers greatly enhance clinical decision-making in urgent cardiovascular care.
Prominent companies in the cardiac biomarker market are dedicated to developing innovative assays to expand their product portfolios, aiming to enhance patient outcomes and address unmet medical needs. These innovative biomarker assays contribute to advancements in cardiac diagnostics, improving accuracy and diagnostic capabilities. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. launched two new cardiac biomarkers, high-sensitivity troponin I (hs-cTnI) and NT-proBNP. These additions augment Mindray's varied portfolio of cardiac biomarkers, bolstering capabilities in diagnosing and managing cardiovascular diseases (CVDs).
In December 2023, Mindray, a medical devices company based in China, acquired DiaSys Diagnostic Systems GmbH for an undisclosed amount. This acquisition aims to strengthen Mindray's global competitiveness in in vitro diagnostics by integrating DiaSys' capabilities and broadening its international presence. DiaSys Diagnostic Systems GmbH, located in Germany, specializes in the field of in vitro diagnostics.
Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics
North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the cardiac biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cardiac biomarkers market consists of sales of assays and reagents, point-of-care testing (POCT) devices, instruments, and software solutions. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cardiac Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cardiac biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cardiac biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiac biomarkers market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.